Eli Lilly's Experimental Obesity Drug Retatrutide Achieves Significant Weight Loss in Late-Stage Clinical Trial

Eli Lilly's Retatrutide Shows Promise in Obesity Treatment

Eli Lilly's experimental obesity drug, retatrutide, has delivered one of the most dramatic weight-loss outcomes seen in a late-stage trial, strengthening the case for a new class of next-generation metabolic therapies that could rival bariatric surgery in effectiveness.

In results from its pivotal Phase 3 TRIUMPH-1 trial, Lilly reported that patients on the highest 12 mg dose lost an average of 31.9 kg, or 28.3 percent of body weight over 80 weeks, while nearly 45 percent of participants achieved at least 30 percent weight loss. This level of weight loss approaches the results historically associated with bariatric surgery, which has long been considered the most effective treatment for severe obesity.

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

The scale of weight loss seen with once-a-week retatrutide injection could reshape obesity care by offering a non-surgical option with comparable outcomes, expanding access for millions of patients globally and intensifying competition in a market already transformed by GLP-1 drugs. The results also suggest durability, with patients continuing treatment for 104 weeks achieving up to 30.3 percent weight loss, equivalent to 38.5 kg, indicating sustained and progressive benefits.

Unlike existing drugs that target one or two metabolic pathways, retatrutide is a first-in-class triple agonist, activating receptors for GIP, GLP-1 and glucagon—hormones involved in appetite, metabolism and energy expenditure. This multi-target approach appears to be driving the step-up in efficacy, with meaningful weight reduction seen across all tested doses.

The lowest 4 mg dose delivered an average 19 percent weight loss, highlighting the drug's flexibility for different patient segments, including those seeking moderate weight reduction with fewer side effects. At higher doses, a majority of patients moved out of the obesity category, with 65.3 percent achieving a BMI below 30—a threshold considered non-obese. Lilly also reported that beyond weight loss, the therapy improved key cardiometabolic markers, including cholesterol, triglycerides, blood pressure and inflammation levels—critical factors given obesity's link to cardiovascular disease.

Tolerability remains a factor, with the most common side effects—nausea, diarrhoea and vomiting—being broadly consistent with other incretin-based therapies. Discontinuation rates increased with higher doses, though most adverse events were mild to moderate.

Read also: US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline

For Lilly, the data reinforces its strategy to dominate the fast-growing obesity market. The company already markets Zepbound and Mounjaro and is building a broader cardiometabolic pipeline. "Retatrutide offers the potential for a patient-centric approach to obesity," said Kenneth Custer, executive vice president at Lilly. The company said additional Phase 3 trials are underway, including studies in patients with diabetes and cardiovascular disease.